Advertisement
Horizon Therapeutics To Buyback Up To $500 Mln Of Ordinary Shares
RTTNews
|
1083 dagar sedan

(RTTNews) - Biotechnology company Horizon Therapeutics plc (HZNP) today announced that its Board of Directors authorized the repurchase of up to $500 million of the Company's ordinary shares.
Under the program, the Company may repurchase ordinary shares from time to time on the open market or through privately negotiated transactions or structured repurchase transactions.
As of June 30, 2022, the Company had cash and cash equivalents of $1.89 billion. The Company expects to fund the repurchase of its ordinary shares under the program with existing cash and cash equivalents.
read more
Amgen, Horizon Therapeutics Reach Settlement On FTC Lawsuit; Seeks To Close Acquisition In Q4
Amgen (AMGN) and Horizon Therapeutics plc (HZNP) announced Friday the entry into a consent order agreement with the Federal Trade Commission (FTC) that resolves the pending FTC administrative lawsuit. This clears the path to take the final steps to close Amgen's $27.8 billion acquisition of Horizon.
RTTNews
|
726 dagar sedan
Horizon Says UPLIZNA Approved By Brazilian Health Regulatory Agency As Monotherapy For NMOSD
Biotechnology company Horizon Therapeutics plc (HZNP) announced Tuesday that the Brazilian Health Regulatory Agency (ANVISA) has approved UPLIZNA as a monotherapy for the treatment of adult patients with NMOSD who are AQP4-IgG+.
RTTNews
|
981 dagar sedan
Xeris Biopharma Inks Research Collaboration With Horizon Therapeutics To Develop Teprotumumab
Biopharmaceutical company Xeris Biopharma Holdings, Inc. (XERS) announced Wednesday that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (HZNP).
RTTNews
|
1008 dagar sedan
Horizon Says Phase 2 Trial Of Dazodalibep To Treat Sjögren's Syndrome Met Primary Endpoint
Horizon Therapeutics plc (HZNP) announced Monday that its Phase 2 trial evaluating dazodalibep for the treatment of Sjögren's syndrome met the primary endpoint in patients with moderate-to-high systemic disease activity. Sjögren's syndrome is a disease with no FDA-approved treatments available.
RTTNews
|
1080 dagar sedan
Asian Markets Trade Mostly Higher
Asian stock markets are mostly higher on Thursday, following the broadly positive cues from Wall Street overnight, as traders remain optimistic the US Fed will cut interest rates at their next meeting in September. They also remain cautious ahead of the release of key US economic data later in the week, including second quarter GDP and the Fed's preferred readings on consumer price inflation.
RTTNews
|
13 minuter sedan
Sensex, Nifty Set To Open Lower As New U.S. Tariffs Take Effect
Indian shares may open on a weak note on Thursday after U.S. President Donald Trump's 50 percent tariffs on Indian goods came into effect on Wednesday.
RTTNews
|
44 minuter sedan
Swiss Market Settles Modestly Higher
The Switzerland market closed modestly higher on Wednesday after staying firm right through the day's session, thanks to fairly strong buying at several counters.
The benchmark SMI closed up by 46.23 points or 0.38% at 12,207.12. The index moved between 12,166.23 and 12,226.36 during the session.
RTTNews
|
56 minuter sedan
Japanese Market Notably Higher
The Japanese market is trading notably higher on Thursday after opening in the red, extending the gains in the previous session, following the broadly positive cues from Wall Street overnight. The Nikkei 225 is moving well above the 42,650 level, with gains in index heavyweights, automakers and financial stocks.
RTTNews
|
1h 4minuter sedan